Table of Contents
3D Bioprinting Market Overview
3D bioprinting integrates additive manufacturing with biology, constructing three-dimensional structures using bio-inks containing living cells and biomaterials.
It operates on a layer-by-layer deposition principle, maintaining cell viability and precision to mimic the complexity of biological tissues.
Applications span tissue engineering for organ regeneration, physiologically relevant drug testing, and personalized medicine through patient-specific implants.
Despite challenges such as scalability and vascularization, interdisciplinary efforts drive rapid advancements.
3D bioprinting promises transformative impacts in regenerative medicine and healthcare. Revolutionizing organ replacement and disease modeling while advancing personalized treatment approaches.
Market Drivers
Several factors drive the global 3D bioprinting market. Firstly, the rising demand for organ transplantation and tissue engineering. Alongside the scarcity of donor organs, spurs investment in bioprinting technologies.
Additionally, advancements in biomaterials and bioinks expand the applications of bioprinted tissues in regenerative medicine and drug discovery.
Increased investments in healthcare infrastructure and government initiatives in biotechnology further fuel market growth.
Collaboration between academia, research institutions, and industry players accelerates innovation and commercialization.
Lastly, the growing prevalence of chronic diseases drives the adoption of bioprinting for personalized medicine.
These factors collectively contribute to the market’s robust growth, positioning it as a crucial driver of next-generation healthcare solutions.
Market Size
The global 3D bioprinting market is projected to reach approximately USD 6.9 billion by 2032. Up from USD 1.6 billion in 2022, with a compound annual growth rate (CAGR) of 16.1% from 2022 to 2032.
List of Major Companies
These are the top 10 companies operating in the 3D Bioprinting Market:
- Organovo
- BICO
- EnvisionTEC
- Aspect-Biosystems
- 3D-Systems
- Stratasys
- Materialise
- Protolabs
- Desktop-Metal
- General-Electric
Organovo
Company Overview
| Establishment Year | 2007 |
| Headquarter | San Diego, California, USA |
| Key Management | Taylor J. Crouch (CEO) |
| Revenue (US$ Bn) | $ 370.0 Million (2022) |
| Headcount | ~ 15 (2022) |
| Website | http://www.organovo.com/ |
About Organovo Holdings
Organovo Holdings Inc., a key player in the 3D bioprinting sector, has been actively developing its lead product. FXR314, for inflammatory bowel diseases, showcasing promising preclinical results in 3D human tissue models.
This progress was recently highlighted at the Crohn’s and Colitis Congress, emphasizing improved epithelial barrier function and fibrosis reduction.
The company, headquartered in San Diego, continues to innovate, pushing forward with clinical studies aimed at transforming drug discovery and therapeutic applications.
Geographical Presence
Organovo Holdings Inc., headquartered in San Diego, California, is a key player in bioprinting and tissue engineering with a global reach.
Through strategic partnerships worldwide, spanning North America, Europe, and Asia-Pacific. The company facilitates knowledge exchange and technological advancements in its field.
Renowned for its innovative products, Organovo has gained international recognition and adoption, strengthening its position in the global biotechnology market.
Leveraging its extensive network of academic institutions, research centers, and biotech companies. Organovo continues to drive innovation and commercialization efforts, establishing itself as a pivotal player in the international biotechnology landscape.
Recent Developments
- In January 2024, Organovo revealed preclinical findings from its FXR314 development program. Showcasing data in its unique 3D human tissue models of Crohn’s disease and ulcerative colitis.
- In December 2023, Organovo disclosed plans to unveil comprehensive Phase 2a trial results for FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024.
BICO
Company Overview
| Establishment Year | 2016 |
| Headquarter | Gothenburg, Sweden |
| Key Management | Erik Gatenholm (Chief Executive) |
| Revenue (US$ Bn) | $ 212.1 M (2023) |
| Headcount | ~ 884 (2023) |
| Website | http://bico.com/ |
About Bico Group
In 3D bioprinting, Bico Group is known for its cutting-edge technologies and strategic moves. Recent developments indicate the company’s dedication to expansion and innovation.
Following its merger with BioTech Innovations Inc., Bico Group has strengthened its market presence, fostering collaborative research and development efforts.
Additionally, the launch of a new biocompatible ink formulation showcases their commitment to advancing bioprinting capabilities for tissue engineering.
With significant funding from venture capitalists, Bico Group is poised for future growth and technological advancement. Shaping the landscape of 3D bioprinting in healthcare and biotechnology.
Monitoring Bico Group’s trajectory is crucial for market analysts as it continues to make tangible contributions to the field.
Geographical Presence
Bico Group, a significant market player, has a robust global presence. In North America, it targets innovative industries in the US and Canada, while in Europe, it focuses on sophisticated markets such as the UK, Germany, and France.
Expanding into the Asia-Pacific region, including China, India, and Japan, taps into rapid market growth. In Latin America, Bico Group extends its reach to Brazil, Mexico, and Argentina, accessing a growing consumer base.
Additionally, its presence in the Middle East and Africa, covering the UAE, South Africa, and Nigeria, underscores its commitment to global expansion and market leadership.
This diverse presence allows Bico Group to adapt to evolving market dynamics and achieve sustainable global growth.
Recent Developments
- In December 2023, Biosero, a subsidiary of BICO specializing in laboratory automation solutions for advancing scientific research, secured a $28 million agreement with a leading global life science firm. The deal involves creating an automated R&D platform, comprising both hardware and software components, across five sub-projects.
- In February 2023, BICO Group unveiled The Nucleus™ Automation Ecosystem, a seamlessly integrated platform revolutionizing modularity, flexibility, and scalability in manufacturing.
EnvisionTEC
Company Overview
| Establishment Year | 2002 |
| Headquarter | Dearborn, Michigan, United States |
| Key Management | Al Siblani (CEO) |
| Revenue (US$ Bn) | $ 36.1 Million (2023) |
| Headcount | ~ 193 (2023) |
| Website | http://envisiontec.com/ |
About EnvisionTEC
EnvisionTEC is a prominent player in the 3D bioprinting sector, renowned for its advanced printing systems catering to various industries, including bioprinting.
The company offers high-resolution printers capable of handling biomaterials to fabricate tissue constructs and organ models.
Recent developments by EnvisionTEC include the expansion of its product portfolio with the launch of new bioprinting solutions aimed at enhancing precision and scalability in tissue engineering applications.
Additionally, EnvisionTEC has been actively involved in strategic partnerships and collaborations to advance its bioprinting technology further and expand its market reach. Indicating a commitment to driving innovation and growth in the 3D bioprinting sector.
Geographical Presence
EnvisionTEC, a major player in professional 3D printing solutions, has a strong global presence across continents.
It strategically operates in North America, focusing on innovation hubs like Detroit, New York, and Europe, benefiting from Germany’s engineering expertise and the UK’s research capabilities.
In the Asia-Pacific region, it targets markets such as China and Japan, which are known for advanced manufacturing.
Additionally, it expands into emerging markets in South America and the Middle East. This extensive reach underscores EnvisionTEC’s commitment to diverse industries. Cementing its position as a key player in the global additive manufacturing sector.
Recent Development
- In January 2021, Desktop Metal entered a definitive agreement to acquire EnvisionTEC.
Aspect-Biosystems
Company Overview
| Establishment Year | 2013 |
| Headquarter | Vancouver, Canada |
| Key Management | Tamer Mohamed (CEO) |
| Revenue (US$ Bn) | $ 20.8 Million (2023) |
| Headcount | ~ 101 (2023) |
| Website | https://www.aspectbiosystems.com/ |
About Aspect Biosystems
Aspect Biosystems, a leader in Canadian 3D bioprinting, focuses on replicating human tissues. The firm recently raised $20 million in Series A funding to enhance its bioprinting capabilities and expand its team.
Significant partnerships include a $2.6 billion agreement with Novo Nordisk to create tissue therapeutics for diabetes and obesity and a $2.2 million cancer drug project.
They are also collaborating with Maastricht University on kidney tissue development and with Johnson & Johnson on bio-printed tissues for knee repair.
These efforts position Aspect Biosystems at the forefront of medical innovation in regenerative medicine.
Geographical Presence
Aspect Biosystems, headquartered in Vancouver, Canada, is a pioneering biotech firm specializing in 3D bioprinting for human tissues.
Though based in Vancouver, it has expanded globally, collaborating with top institutions in the United States, Europe, and Asia.
In the US, it works with leading academic and research bodies in tissue engineering and regenerative medicine.
In Europe, it partners with key academic centers and biotech companies to capitalize on the region’s healthcare innovation focus.
Similarly, in Asia, Aspect Biosystems fosters ties with academic and industry players to tap into the growing interest in bioprinting and regenerative medicine.
This global reach underscores the company’s commitment to advancing bioprinting and driving progress in regenerative medicine through strategic partnerships and innovation.
Recent Development
- In April 2023, Aspect Biosystems and Novo Nordisk joined forces in a collaboration, development, and licensing deal to create bioprinted tissue therapeutics. These therapeutics aim to replace, repair, or enhance biological functions in the body, to offer innovative treatments for diabetes and obesity that can fundamentally modify these conditions.
- In March 2023, Aspect Biosystems secured more than $3.6 million in funding from the Canadian government.
3D-Systems
Company Overview
| Establishment Year | 1986 |
| Headquarter | Rock Hill, South Carolina, U.S. |
| Key Management | Jeff Graves (President & CEO) |
| Revenue (US$ Bn) | $ 538.0 M (2022) |
| Headcount | ~ 2,032 (2022) |
| Website | http://3dsystems.com/ |
About 3D Systems Corporation
3D Systems Corporation has enhanced its role in the 3D bioprinting sector, particularly through the development of the “Print to Perfusion” process that supports the printing of complex, vascularized tissues essential for organ manufacturing with United Therapeutics Corporation.
Expanding its footprint into biopharmaceuticals, the company launched Systemic Bio™. Focused on bioprinting organ-on-a-chip platforms for drug development, backed by a $15 million investment.
Additionally, 3D Systems acquired Volumetric to boost its capabilities in tissue and organ manufacturing. It has initiated R&D projects for bioprinting patient-specific soft tissues, like breast tissue for reconstructive surgeries, addressing increasing clinical demands.
These strategic initiatives reflect 3D Systems’ commitment to leveraging its bioprinting innovations to transform medical care and pharmaceutical testing.
Geographical Presence
3D Systems Corporation strategically places itself in key global regions, ensuring a strong presence to meet diverse market needs.
Rooted in North America, especially the USA and Canada, the company utilizes its Rock Hill, South Carolina headquarters for local partnerships.
Expanding into Europe, including Germany, the UK, and France, it taps into the growing demand for additive manufacturing.
Additionally, it ventures into Asia-Pacific markets like China, Japan, and South Korea, recognizing its growth potential.
Through collaborations with local partners, 3D Systems aims to address evolving industry demands worldwide, positioning for continuous innovation in advanced manufacturing.
Recent Developments
- In September 2022, 3D Systems announced the creation of Systemic Bio™, a new biotech company aimed at speeding up drug discovery and development.
- In January 2021, 3D Systems announced plans to greatly increase its efforts in developing regenerative medicine and bioprinting solutions.
Stratasys
Company Overview
| Establishment Year | 1989 |
| Headquarter | Eden Prairie, Minnesota, U.S. |
| Key Management | Yoav Zeif (CEO) |
| Revenue (US$ Bn) | $ 628 Million (2023) |
| Headcount | ~ 1,980 (2023) |
| Website | http://stratasys.com/ |
About Stratasys
Stratasys Ltd., a leader in polymer 3D printing solutions, has recently enhanced its focus on the 3D bioprinting sector through a strategic partnership with CollPlant Biotechnologies.
This collaboration aims to revolutionize healthcare by industrial-scale bioprinting of tissues and organs, initially concentrating on regenerative breast implants using CollPlant’s plant-based rhCollagen bio-inks and Stratasys’s advanced P3 3D printing technology.
This initiative not only targets a significant portion of the $2.6 billion global breast implant market but also promises an innovative alternative to traditional procedures by encouraging the regeneration of natural breast tissues without eliciting an immune response.
This partnership is part of Stratasys’s broader strategy to deliver integrated solutions for high-growth industries, potentially leveraging their precision 3D printing capabilities to transform areas like cosmetic and reconstructive surgery.
Geographical Presence
Stratasys Ltd, a key player in 3D printing, has a strong global presence spanning North America, Europe, Asia-Pacific, and the Middle East.
Based in Minnesota, USA, it has offices and manufacturing sites strategically located across these regions. In Europe, it has key locations in Germany, France, the UK, and Belgium, serving various industries.
In Asia-Pacific, it operates in China, Japan, South Korea, India, and Singapore to tap into growing markets. Its presence in the Middle East, including Israel and the UAE, highlights its commitment to global expansion.
This strategic distribution positions Stratasys as a leading provider of localized support and innovative solutions worldwide.
Recent Developments
- In November 2023, Stratasys Ltd collaborated with Siemens Healthineers on a groundbreaking research endeavor aimed at creating innovative solutions for enhancing medical imaging phantoms used in computed tomography (CT) imaging.
- In April 2023, CollPlant Biotechnologies and Stratasys Ltd partnered to develop and commercialize a method for bio-fabricating human tissues and organs. This collaboration utilizes CollPlant’s rh-Collagen-based bioinks and Stratasys’s P3 technology-based bioprinter.
Materialise
Company Overview
| Establishment Year | 1990 |
| Headquarter | Leuven, Belgium |
| Key Management | Brigitte de Vet-Veithen (CEO) |
| Revenue (US$ Bn) | $ 244.0 Million (2022) |
| Headcount | ~ 2,433 (2022) |
| Website | http://www.materialise.com/ |
About Materialise
Materialise NV is making significant strides in the 3D bioprinting sector, especially within medical applications.
The company has strengthened its partnership with Siemens to deliver advanced 3D printing capabilities worldwide, enabling radiologists to transform patient scan data into 3D models through Materialise’s Mimics inPrint software, which integrates with Siemens Healthineers’ systems.
This collaboration aims to enhance diagnostic and therapeutic planning. Additionally, Materialise has entered the U.S. market with its custom 3D-printed titanium facial implants, emphasizing its focus on personalized medical devices.
Financially, the company reported a 12.9% revenue increase in 2022, primarily driven by its medical segment, with expectations for continued growth in 2023.
These efforts highlight Materialise’s commitment to advancing 3D printing in healthcare, fostering more personalized and effective treatments.
Geographical Presence
Materialise NV has a global presence in the additive manufacturing and 3D printing industry. It is headquartered in Leuven, Belgium, and serves as the central hub for its European operations.
Expanding strategically into key markets like North America, the company has established offices and facilities in Plymouth, Michigan, and Sunnyvale, California, catering to sectors such as healthcare and aerospace.
In the Asia-Pacific region, Materialise has offices, collaborations, and production facilities in China, Japan, and Singapore, leveraging local partnerships effectively.
Through alliances, distribution networks, and online platforms, Materialise extends its global reach as a leading provider of additive manufacturing solutions across diverse industries and regions.
Recent Developments
- In February 2024, Materialise introduced the Personalized TMJ Total Arthroplasty System, aimed at addressing the needs of patients undergoing total temporomandibular joint (TMJ) arthroplasty.
- In November 2023, Materialise unveiled Mimics Flow Case Management, designed as a solution for managing cases in hospital-based 3D printing labs at the point of care.
Protolabs
Company Overview
| Establishment Year | 1999 |
| Headquarter | Maple Plain, Minnesota, U.S. |
| Key Management | Robert Bodor (CEO) |
| Revenue (US$ Bn) | $ 503.9 Million (2022) |
| Headcount | ~ 2,415 (2022) |
| Website | http://www.protolabs.com/ |
About Protolabs
Protolabs has significantly advanced in the 3D bioprinting sector with its rapid prototyping and on-demand production.
The company recently acquired 3D Hubs, enhancing its digital manufacturing capabilities and extending its global presence.
This merger aims to form the largest manufacturing platform, combining Protolabs’ efficiency with 3D Hubs’ diverse production methods.
Financially, Protolabs is capitalizing on its digital model to offer quick, extensive services, showcasing a broad array of materials and technologies.
This development highlights Protolabs’ ongoing efforts to lead the industry by expanding its services and facilitating access to sophisticated manufacturing techniques worldwide.
Geographical Presence
Protolabs, headquartered in Maple Plain, Minnesota, is a key player in digital manufacturing, boasting a global reach across North America, Europe, and Asia.
In North America, it operates strategically located facilities in states like Minnesota, North Carolina, New Hampshire, and California, ensuring efficient service delivery.
Overseas, Protolabs has manufacturing sites in the UK and Germany, serving various sectors such as automotive, aerospace, and medical devices.
Expanding into Asia, it has facilities in Japan and a presence in Singapore, meeting the demands of rapidly evolving markets.
This widespread presence reflects Protolabs’ dedication to providing cutting-edge manufacturing solutions worldwide. Including rapid prototyping and on-demand production tailored to diverse industry needs.
Recent Development
- In January 2024, Protolabs rebranded its service to Protolabs Network. Which utilizes global manufacturing partners to enhance capabilities and offer diverse pricing options.
- In July 2023, Protolabs enhanced its CNC machining capabilities by providing rapid anodizing and chromate plating services for aluminum components. Customers can now obtain customized machined parts with plating within a speedy four-day turnaround, spanning from quote to manufacturing to shipping.
Desktop-Metal
Company Overview
| Establishment Year | 2012 |
| Headquarter | Burlington, Massachusetts, United States |
| Key Management | Ric Fulop (CEO) |
| Revenue (US$ Bn) | $ 190 Million (2023) |
| Headcount | ~ 950 (2023) |
| Website | http://desktopmetal.com/ |
About Desktop Metal
Desktop Metal, Inc., renowned for its metal 3D printing innovations, has ventured into 3D bioprinting through its subsidiary, Desktop Health.
This branch is focused on developing fabrication technologies to enhance personal healthcare. A key product from Desktop Health is the 3D-Bioplotter, a leading bio-fabrication device since 2000.
It is known for its versatility and significant role in medical research, with support from over 600 research studies.
Recently, Desktop Health has upgraded the 3D-Bioplotter with new build platforms and dual-functionality printheads, enhancing its flexibility and efficiency.
These updates highlight Desktop Metal’s dedication to advancing 3D printing technologies in healthcare, providing innovative solutions for complex medical challenges.
Geographical Presence
Desktop Metal, Inc. strategically situates itself in key regions to seize emerging markets and address diverse client needs.
With a strong focus on North America, particularly the U.S., where its headquarters reside in Massachusetts, the company fosters innovation and collaborations with industry leaders.
It expands into Europe, tapping into advanced manufacturing ecosystems in countries like Germany, the UK, and France, utilizing partnerships and distribution networks to serve local markets.
In the Asia-Pacific region, including China, Japan, and South Korea, Desktop Metal targets dynamic manufacturing landscapes and growing 3D printing adoption, strengthening its global strategy.
Through strategic partnerships worldwide, the company extends its market reach, providing comprehensive support to customers globally.
Recent Development
- In March 2024, Desktop Health introduced ScanUp, a program tailored for dentists, aiming to streamline the integration of digital technologies to enhance both practice efficiency and patient care.
- In October 2023, Desktop Metal, Inc. unveiled Live Monitor™, a software application designed to offer real-time data from printing systems, enhancing efficiency and management for individual systems or entire fleets.
General-Electric
Company Overview
| Establishment Year | 1892 |
| Headquarter | Boston, Massachusetts, U.S. |
| Key Management | H. Lawrence Culp Jr. (Chairman and CEO) |
| Revenue (US$ Bn) | $ 68 Billion (2023) |
| Headcount | ~ 125,000 (2023) |
| Website | https://www.ge.com/ |
About General Electric Company
General Electric Company (GE) is actively advancing its role in the 3D bioprinting sector, focusing on the development of technologies that fabricate complex tissues and biomaterials for medical applications.
These efforts align with GE’s broader strategy to enhance its technological capabilities across various sectors, including healthcare.
As part of a strategic restructuring, GE has announced the spin-off of GE Vernova, which is set to begin trading independently in April 2024.
This restructuring aims to sharpen GE’s focus on core areas such as aerospace and energy, potentially incorporating advanced manufacturing technologies like 3D bioprinting.
This move reflects GE’s commitment to innovation and its intention to integrate 3D bioprinting technologies into its operational scope, particularly within GE Aerospace.
Geographical Presence
General Electric (GE), a global conglomerate, has a vast presence across multiple countries and regions worldwide, including North America, Europe, Asia-Pacific, and beyond.
In North America, the United States serves as its primary base, alongside notable operations in Canada. Europe hosts GE facilities and offices in key countries like the UK, Germany, France, Italy, and Switzerland.
In the Asia-Pacific region, GE has significant footholds in China, India, Japan, South Korea, Australia, and Singapore.
Furthermore, GE extends its reach to Latin America, the Middle East, and Africa, strategically positioning itself to leverage diverse market opportunities and establish a strong international presence.
Recent Developments
- In April 2024, GE Aerospace officially emerged as an independent publicly traded company, shaping the future of aviation post the GE Vernova spin-off.
- In February 2024, General Electric authorized the previously disclosed spin-off of GE Vernova.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
